These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 18798220

  • 1. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A.
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [Abstract] [Full Text] [Related]

  • 2. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.
    Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, Dréno B, Jacques Y, Godard A, Blanchard F.
    J Pathol; 2009 Apr; 217(5):665-76. PubMed ID: 19097071
    [Abstract] [Full Text] [Related]

  • 3. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
    Lu C, Rak JW, Kobayashi H, Kerbel RS.
    Cancer Res; 1993 Jun 15; 53(12):2708-11. PubMed ID: 8504408
    [Abstract] [Full Text] [Related]

  • 4. Loss of oncostatin M receptor beta in metastatic melanoma cells.
    Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, Godard A, Blanchard F.
    Oncogene; 2007 Feb 08; 26(6):881-92. PubMed ID: 16909117
    [Abstract] [Full Text] [Related]

  • 5. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    J Immunother; 2009 May 08; 32(4):415-23. PubMed ID: 19342963
    [Abstract] [Full Text] [Related]

  • 6. Tissue prognostic markers for adoptive immunotherapy in melanoma.
    Quereux G, Pandolfino MC, Knol AC, Khammari A, Volteau C, Nguyen JM, Dreno B.
    Eur J Dermatol; 2007 May 08; 17(4):295-301. PubMed ID: 17540635
    [Abstract] [Full Text] [Related]

  • 7. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA.
    Clin Cancer Res; 2005 Sep 01; 11(17):6400-7. PubMed ID: 16144945
    [Abstract] [Full Text] [Related]

  • 8. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
    Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B, Schachter J.
    Isr Med Assoc J; 2006 Mar 01; 8(3):164-8. PubMed ID: 16599050
    [Abstract] [Full Text] [Related]

  • 9. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    Clin Cancer Res; 2010 May 01; 16(9):2646-55. PubMed ID: 20406835
    [Abstract] [Full Text] [Related]

  • 10. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
    Wagley Y, Yoo YC, Seo HG, Rhee MH, Kim TH, Kang KW, Nah SY, Oh JW.
    Biochem Biophys Res Commun; 2007 Mar 23; 354(4):985-91. PubMed ID: 17274948
    [Abstract] [Full Text] [Related]

  • 11. Development of an effective method for dendritic cell immunotherapy of mouse melanoma.
    Lee TH, Cho HK, Cho YH, Lee MG.
    Scand J Immunol; 2009 Aug 23; 70(2):85-92. PubMed ID: 19630913
    [Abstract] [Full Text] [Related]

  • 12. Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?
    Peuvrel L, Nguyen JM, Khammari A, Quereux G, Brocard A, Dreno B.
    J Eur Acad Dermatol Venereol; 2011 Nov 23; 25(11):1311-7. PubMed ID: 21348897
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
    Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP.
    Cancer Res; 1995 May 15; 55(10):2200-5. PubMed ID: 7743524
    [Abstract] [Full Text] [Related]

  • 14. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee.
    Clin Cancer Res; 2011 Apr 01; 17(7):1664-73. PubMed ID: 21325070
    [Abstract] [Full Text] [Related]

  • 15. The DNA ploidy and proliferative activity of transplantable melanoma cells in regard to their secretory function.
    Wachulska M, Kozłowska K, Cichorek M.
    Neoplasma; 2005 Apr 01; 52(4):280-6. PubMed ID: 16059642
    [Abstract] [Full Text] [Related]

  • 16. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
    Reali UM, Martini L, Borgognoni L, Semino C, Pietra G, Chiarugi C, Guastella M, Melioli G.
    Melanoma Res; 1998 Feb 01; 8(1):77-82. PubMed ID: 9508381
    [Abstract] [Full Text] [Related]

  • 17. Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
    Xu Y, Zhang F, Qin L, Miao J, Sheng W, Xie Y, Xu X, Yang J, Qian H.
    Melanoma Res; 2014 Feb 01; 24(1):20-31. PubMed ID: 24300090
    [Abstract] [Full Text] [Related]

  • 18. Cytokine-based therapy for melanoma: pre-clinical studies.
    Shurin MR, Kirkwood JM, Esche C.
    Forum (Genova); 2000 Feb 01; 10(3):204-26. PubMed ID: 11007930
    [Abstract] [Full Text] [Related]

  • 19. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
    Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR.
    Cancer Res; 1992 Dec 01; 52(23):6561-6. PubMed ID: 1423301
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
    Möller P, Wittig B, Schadendorf D.
    Anticancer Res; 1998 Dec 01; 18(2B):1237-41. PubMed ID: 9615794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.